Details
Stereochemistry | RACEMIC |
Molecular Formula | C18H14Cl2N2.HNO3 |
Molecular Weight | 392.236 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O[N+]([O-])=O.ClC1=CC(Cl)=C2C(N3C=CN=C3)C4=CC=CC=C4CCC2=C1
InChI
InChIKey=DPHMSVRBAXJSPF-UHFFFAOYSA-N
InChI=1S/C18H14Cl2N2.HNO3/c19-14-9-13-6-5-12-3-1-2-4-15(12)18(17(13)16(20)10-14)22-8-7-21-11-22;2-1(3)4/h1-4,7-11,18H,5-6H2;(H,2,3,4)
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/22421664
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22421664
Eberconazole is an antifungal drug with broad antimicrobial spectrum of activity. The drug was developed and approved in Spain (Ebernet 1% cream) for the treatment of tinea. Eberconazole exerts fungicidal or fungistatic activity depending on concentration, being fungicidal at higher concentration and fungistatic at lower concentrations. Eberconazole prevents fungal growth by inhibiting ergosterol synthesis, an essential component of the fungal cytoplasmic membrane leading to structural and functional changes. It prevents the fungal ergosterol synthesis by inhibiting lanosterol 14alpha-demethylase enzyme that is responsible for the formation of 14 alpha-methylsterols (precursor of ergosterols).
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Lanosterol 14-alpha demethylase Sources: https://www.ncbi.nlm.nih.gov/pubmed/22421664 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | EBERNET Approved UseEBERNET 1% cream is indicated in the cutaneous treatment of the following infections caused by Fungi: Tinea corporis, Tinea cruris and Tinea pedis. Launch Date2004 |
|||
Curative | EBERNET Approved UseEBERNET 1% cream is indicated in the cutaneous treatment of the following infections caused by Fungi: Tinea corporis, Tinea cruris and Tinea pedis. Launch Date2004 |
|||
Curative | EBERNET Approved UseEBERNET 1% cream is indicated in the cutaneous treatment of the following infections caused by Fungi: Tinea corporis, Tinea cruris and Tinea pedis. Launch Date2004 |
PubMed
Title | Date | PubMed |
---|---|---|
[Topical treatment with eberconazole of the experimental guinea pig cutaneous candidosis.]. | 1999 Mar |
|
In vitro susceptibilities of clinical yeast isolates to the new antifungal eberconazole compared with their susceptibilities to clotrimazole and ketoconazole. | 1999 May |
|
In vitro activities of the new antifungal drug eberconazole and three other topical agents against 200 strains of dermatophytes. | 2003 Nov |
|
Evaluation of disk diffusion method for determining eberconazole susceptibility of dermatophytes and influence of culture medium. | 2005 May |
|
Eberconazole--pharmacological and clinical review. | 2012 Mar-Apr |
Patents
Sample Use Guides
Eberconazole (Ebernet 1% cream) should be applied twice a day for 4 weeks. The cream should be applied in sufficient quantity to cover the lesion and surroundings, and should be distributed with the aid of a light massage.
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14605165
Antifungal activity of eberconazole was tested against 200 strains of dermatophytes. The MIC50 values were 0.06 ug/ml (E. floccosum, M. audouinii, M. canis, M. gypseum, T. ajelloi, T. violaceum), 0.03 ug/ml (M. ferrugineum, M. fulvum, T. balcaneum), 0.25 ug/ml (T. erinacei), 0.125 ug/ml (T. interdigitale, T. mentagrophytes, T. rubrum, T. simii, T. tonsurans).
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000170416
Created by
admin on Sat Dec 16 19:10:49 GMT 2023 , Edited by admin on Sat Dec 16 19:10:49 GMT 2023
|
PRIMARY | |||
|
130104-32-4
Created by
admin on Sat Dec 16 19:10:49 GMT 2023 , Edited by admin on Sat Dec 16 19:10:49 GMT 2023
|
PRIMARY | |||
|
LSL8E59V2V
Created by
admin on Sat Dec 16 19:10:49 GMT 2023 , Edited by admin on Sat Dec 16 19:10:49 GMT 2023
|
PRIMARY | |||
|
179851
Created by
admin on Sat Dec 16 19:10:49 GMT 2023 , Edited by admin on Sat Dec 16 19:10:49 GMT 2023
|
PRIMARY | |||
|
DTXSID80926597
Created by
admin on Sat Dec 16 19:10:49 GMT 2023 , Edited by admin on Sat Dec 16 19:10:49 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD